- Home
- HBNC vs TYRA Comparison
HBNC vs TYRA Comparison
Compare HBNC & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBNC
- TYRA
- Stock Information
- Founded
- HBNC 1873
- TYRA 2018
- Country
- HBNC United States
- TYRA United States
- Employees
- HBNC N/A
- TYRA 38
- Industry
- HBNC Major Banks
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- HBNC Finance
- TYRA Health Care
- Exchange
- HBNC Nasdaq
- TYRA Nasdaq
- Market Cap
- HBNC 692.0M
- TYRA 666.4M
- IPO Year
- HBNC N/A
- TYRA 2021
- Fundamental
- Price
- HBNC $16.77
- TYRA $13.17
- Analyst Decision
- HBNC Hold
- TYRA Strong Buy
- Analyst Count
- HBNC 2
- TYRA 6
- Target Price
- HBNC $19.00
- TYRA $30.50
- AVG Volume (30 Days)
- HBNC 142.3K
- TYRA 247.2K
- Earning Date
- HBNC 01-22-2025
- TYRA 03-18-2025
- Dividend Yield
- HBNC 3.75%
- TYRA N/A
- EPS Growth
- HBNC N/A
- TYRA N/A
- EPS
- HBNC 0.48
- TYRA N/A
- Revenue
- HBNC $183,718,000.00
- TYRA N/A
- Revenue This Year
- HBNC N/A
- TYRA N/A
- Revenue Next Year
- HBNC $18.53
- TYRA N/A
- P/E Ratio
- HBNC $35.22
- TYRA N/A
- Revenue Growth
- HBNC N/A
- TYRA N/A
- 52 Week Low
- HBNC $11.18
- TYRA $11.89
- 52 Week High
- HBNC $19.18
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- HBNC 47.21
- TYRA 43.64
- Support Level
- HBNC $16.49
- TYRA $12.27
- Resistance Level
- HBNC $17.62
- TYRA $13.79
- Average True Range (ATR)
- HBNC 0.64
- TYRA 0.71
- MACD
- HBNC -0.05
- TYRA 0.03
- Stochastic Oscillator
- HBNC 38.51
- TYRA 51.09
About HBNC Horizon Bancorp Inc.
Horizon Bancorp (IN) is a United States-based holding company providing banking services. It is engaged in providing commercial and retail banking services, corporate and individual trust and agency services, and other services incident to banking. The company also provides commercial loans, real estate loans, mortgage warehouse loans, consumer loans, and other credit facilities. The company has one principal business segment, commercial banking.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).